Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D011379:Prognosis; D011869:Radioligand Assay; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid*
D000978:Antiparkinson Agents; D004873:Ergolines; D001971:Bromocriptine; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D002230:Carbidopa